ARTA
ACRS icon

A.R.T. Advisors’s Aclaris Therapeutics ACRS Stock Holding History

A.R.T. Advisors’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-28,971
Closed -$578K – 1368
2018
Q2 		$578K Sell
28,971
-28,329
-49% -$523K 0.02% 863
2018
Q1 		$1M Buy
57,300
+2,600
+5% +$55.1K 0.04% 664
2017
Q4 		$1.35M Buy
+54,700
New +$1.33M 0.06% 505
2017
Q3 		– Sell
-23,600
Closed -$640K – 1309
2017
Q2 		$640K Buy
23,600
+12,200
+107% +$332K 0.03% 689
2017
Q1 		$339K Sell
11,400
-600
-5% -$17.3K 0.02% 958
2016
Q4 		$325K Buy
+12,000
New +$306K 0.02% 919

Other funds holding ACRS

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
PC
Polar Capital London, United Kingdom $13.5B AUM 55.9% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

A.R.T. Advisors's ACRS Position: Q3 2018 in Review

A.R.T. Advisors sold out of Aclaris Therapeutics (ACRS) in Q3 2018, closing a stake of 28,971 shares — an estimated $578K sold.

A.R.T. Advisors first reported a position in ACRS in Q4 2016 and held it in 6 quarters. The position peaked at $1.35M in Q4 2017. 86 funds tracked by Wall St. Rank hold ACRS as of Q3 2018.

  • A.R.T. Advisors reported no remaining Aclaris Therapeutics position as of Q3 2018 after selling out during the quarter.
  • A.R.T. Advisors sold 28,971 Aclaris Therapeutics shares in Q3 2018, an estimated $578K.
  • A.R.T. Advisors first reported a position in Aclaris Therapeutics in Q4 2016 and held it in 6 quarters.
  • A.R.T. Advisors's Aclaris Therapeutics position peaked at $1.35M in Q4 2017.
  • 86 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q3 2018.

Based on A.R.T. Advisors's 13F filing for Q3 2018, filed 14 Nov 2018.